What is he best known for?
The fields of study he is best known for:
- Gene
- Polymer
- Biochemistry
His main research concerns Dendrimer, Drug delivery, Pharmacology, Drug carrier and Microglia.
Rangaramanujam M. Kannan carries out multidisciplinary research, doing studies in Dendrimer and Linker.
His research in Drug delivery intersects with topics in Biophysics, Intracellular and Drug.
His work deals with themes such as Systemic administration, Biodistribution, Pathology, Thymidine and Cytotoxicity, which intersect with Pharmacology.
His Microglia research is multidisciplinary, incorporating perspectives in Surgery, Macular degeneration, Rabbit model, Neuroinflammation and Multiple sclerosis.
His work on Nanotoxicology and Nanodevice as part of general Nanotechnology study is frequently linked to Design elements and principles and Structure control, bridging the gap between disciplines.
His most cited work include:
- Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications (558 citations)
- Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications (558 citations)
- Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers (351 citations)
What are the main themes of his work throughout his whole career to date?
Rangaramanujam M. Kannan mainly focuses on Dendrimer, Microglia, Neuroinflammation, Pharmacology and Drug delivery.
His study in Dendrimer is interdisciplinary in nature, drawing from both Cancer research, Glioblastoma, In vitro, Nanotechnology and Biophysics.
His Microglia study integrates concerns from other disciplines, such as Cell biology, Neuroscience, Neuroprotection and Blood–brain barrier.
His research integrates issues of Systemic administration, Pathogenesis and Targeted drug delivery in his study of Neuroinflammation.
The Pharmacology study combines topics in areas such as Glutamate receptor, Excitotoxicity, Retinal and Surgery.
His Drug delivery research includes elements of Flow cytometry and Drug.
He most often published in these fields:
- Dendrimer (61.47%)
- Microglia (34.40%)
- Neuroinflammation (29.36%)
What were the highlights of his more recent work (between 2017-2021)?
- Dendrimer (61.47%)
- Microglia (34.40%)
- Neuroinflammation (29.36%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Dendrimer, Microglia, Neuroinflammation, Cancer research and Glioblastoma.
The various areas that Rangaramanujam M. Kannan examines in his Dendrimer study include Acetylcysteine, Combinatorial chemistry and Pathology.
His Microglia research is multidisciplinary, incorporating elements of Central nervous system, Neuroprotection, Pharmacology, Immune system and Cell biology.
His work carried out in the field of Neuroinflammation brings together such families of science as Ischemic retinopathy, Biophysics, Targeted drug delivery, Triamcinolone acetonide and Pathological Angiogenesis.
Rangaramanujam M. Kannan focuses mostly in the field of Cancer research, narrowing it down to matters related to Systemic administration and, in some cases, Intracellular, Blood–brain barrier and Brain tumor.
His Zebrafish study combines topics in areas such as Drug delivery and Regeneration.
Between 2017 and 2021, his most popular works were:
- Cognitive impairments induced by necrotizing enterocolitis can be prevented by inhibiting microglial activation in mouse brain (36 citations)
- Targeting Mitochondrial Dysfunction and Oxidative Stress in Activated Microglia using Dendrimer-Based Therapeutics. (36 citations)
- Effect of mannose targeting of hydroxyl PAMAM dendrimers on cellular and organ biodistribution in a neonatal brain injury model. (31 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Polymer
- Biochemistry
The scientist’s investigation covers issues in Microglia, Neuroinflammation, Dendrimer, Pharmacology and Biophysics.
His Microglia research includes themes of Tumor necrosis factor alpha, Ex vivo, Enterocolitis, Neurodegeneration and Programmed cell death.
His studies deal with areas such as Systemic administration and Nanocarriers as well as Neuroinflammation.
His Dendrimer research focuses on Central nervous system and how it connects with Glioblastoma, In vitro and Cell biology.
Rangaramanujam M. Kannan combines subjects such as Immune system, Stimulation, Peroxisome, Adrenoleukodystrophy and Glutamate secretion with his study of Pharmacology.
His work deals with themes such as Targeted drug delivery, Endocytosis, Pinocytosis, Internalization and Flow cytometry, which intersect with Biophysics.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
